A Study With NLY01 in Subjects With Type 2 Diabetes

NCT04159766 · Completed

Last updated 2026-05-28

This clinical trial tests the safety of the experimental drug NLY01 in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 20 people

Who can join Ages 18–65 · all sexes

Timeline Started 2019-10 · est. completion 2020-12

Where 2 sites · Germany

What this study is testing ClinicalTrials.gov NCT04159766 ↗

Description as written by the study sponsor.

This is a Phase 2a study designed to assess the effect of NLY01 in patients with type 2 diabetes. Patients will be monitored for safety, pharmacokinetics, and pharmacodynamic effects on glycemic control.

Treatments tested

NLY01 Drug

NLY01, a PEGylated form of the anti-diabetic peptide exenatide
Placebo Drug

normal saline

Main thing measured	Number of participants with Treatment Emergent Adverse Events
Sponsor	Neuraly, Inc.
Conditions studied	Type2 Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04159766 ↗